GDTC

Company Overview — What Does CytoMed Therapeutics Ltd Do?

We are a pre-clinical biopharmaceutical company focused on harnessing our licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of our novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. We believe that the current development of CD19-targeting CAR-T cells in treating B-cell malignancies signifies that cellular immunotherapy is becoming one of the pillars in cancer care. However, we believe that it remains challenging to apply the current CAR-T principle into treatments of other type of cancers, in particular solid tumors, due to a variety of reasons, including (i) the reliance on the limited cell quality and quantity of patients, (ii) the lack of suitable surface cancer antigens and their recognition system, and (iii) the ability of cancer to escape because of a single antigen-targeting strategy. To this end, we have established two novel patient blood cell-independent platform technologies to manufacture “off-the-shelf” cell-based cancer immunotherapies, meaning the manufacturing of the stated cell therapies in quantities, which utilizes either donor blood cells or iPSCs as starting materials, but not the limited patient’s own blood cells and no matching is required between such donor and recipient of the product. Our two novel platforms depend on healthy donor blood cells and induced pluripotent stem cells as starting material. Such platform technologies and the resulting product candidates exploit the multiple antigen recognition systems of NK cells and gamma delta T cells in the human body and so as to recognize and treat a broad range of cancers. Built on proprietary platform technologies, we are developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is our lead product candidate and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. We submitted a CTA application for Phase I clinical trial to HSA, Singapore in December 2021 and, in July 2022, were granted a CTA relating to the use of our CTM-N2D for the ANGELICA Trial to be conducted with the National University Hospital Singapore, subject to conditions specified by the HSA. On January 6, 2023, the HSA acknowledged that we had submitted the relevant documents to meet the approval conditions and no further action was required. On March 10, 2023, we entered into the Clinical Study Agreement pursuant to which the ANGELICA Trial will be conducted by the National University Hospital Singapore to evaluate the safety of CTM-N2D in human subjects. We expect to expand our pipeline further in Phase II trials of CTM-N2D therapy for specific cancer indications. Our second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The hybrid cell express receptors of both cells which potentially allow the gdNKT cells to recognize and treat a broad range of cancers. This product is currently undergoing pre-clinical development. Our third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells and exploits the potential of these cells to recognize and treat a broad range of cancers. We are looking to submit a CTX application for Phase I clinical trial to NPRA, Malaysia after 2023. We have also appointed an agent in the United States to prepare a Drug Master File for a potential research collaboration in the United States. As of the date of this Prospectus, we are a holding company incorporated in Singapore which oversees our operations in Malaysia. We conduct our business activities primarily through our direct wholly-owned subsidiary in Malaysia, CytoMed Malaysia, but may be commencing more research and clinical trial activities in Singapore through CytoMed moving forward. Other than CytoMed Malaysia, our other subsidiaries have minimal operations as of the date of this Prospectus. We have an operating cGMP Facility in Johor, Malaysia (which is near Singapore) which has been built in accordance with the international PIC/S GMP standards for the manufacture of cell therapy products and clinical trials. In addition, we have a well-trained operations team who conducts all essential cGMP activities including manufacture, quality control, quality assurance and documentation. We manufacture our product candidates in our cGMP Facility instead of engaging and relying on an external CMO. As of the date of this Prospectus, the registrant is a public company limited by shares known as CytoMed Therapeutics Limited. On January 19, 2023, the registrant converted from a private company limited by shares incorporated in Singapore, known as CytoMed Therapeutics Pte. Ltd. to a public company limited by shares pursuant to the provisions of the Singapore Companies Act. Our principal executive office in Singapore is located at 1 Commonwealth Lane, #08-22, Singapore. CytoMed Therapeutics Ltd (GDTC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chee Kong Choo. With a market capitalization of $12M, GDTC is one of the notable companies in the Healthcare sector.

CytoMed Therapeutics Ltd (GDTC) Stock Rating — Reduce (April 2026)

As of April 2026, CytoMed Therapeutics Ltd receives a Reduce rating with a composite score of 29.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GDTC ranks #3,632 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CytoMed Therapeutics Ltd ranks #591 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GDTC Stock Price and 52-Week Range

CytoMed Therapeutics Ltd (GDTC) currently trades at $1.00. The 52-week high for GDTC is $3.68, which means the stock is currently trading -72.8% from its annual peak. The 52-week low is $0.73, putting the stock 37.3% above its annual trough. Recent trading volume was 388 shares, suggesting relatively thin trading activity.

Is GDTC Overvalued or Undervalued? — Valuation Analysis

CytoMed Therapeutics Ltd (GDTC) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.81x, versus the sector average of 2.75x. The price-to-sales ratio is 11.07x, compared to 1.66x for the average Healthcare stock.

At current multiples, CytoMed Therapeutics Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CytoMed Therapeutics Ltd Profitability — ROE, Margins, and Quality Score

CytoMed Therapeutics Ltd (GDTC) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -112.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -100.2% versus the sector average of -33.1%.

On a margin basis, CytoMed Therapeutics Ltd reports gross margins of -347.1%, compared to 71.5% for the sector. The operating margin is -687.1% (sector: -66.1%). Net profit margin stands at -687.1%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GDTC Debt, Balance Sheet, and Financial Health

CytoMed Therapeutics Ltd has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $333,032. Cash and equivalents stand at $4M.

GDTC has a beta of 0.86, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CytoMed Therapeutics Ltd is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CytoMed Therapeutics Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, CytoMed Therapeutics Ltd reported revenue of $268,662. Net income for the quarter was $-2M. Gross margin was -347.1%. Operating income came in at $-2M.

In FY 2024, CytoMed Therapeutics Ltd reported revenue of $268,662. Net income for the quarter was $-2M. Gross margin was -347.1%. Revenue grew 167.6% year-over-year compared to FY 2023. Operating income came in at $-2M.

In FY 2023, CytoMed Therapeutics Ltd reported revenue of $-397,262 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-3M. Revenue grew 53.7% year-over-year compared to FY 2022. Operating income came in at $-3M.

In FY 2022, CytoMed Therapeutics Ltd reported revenue of $-858,078. Net income for the quarter was $-2M. Revenue grew -454.0% year-over-year compared to FY 2021. Operating income came in at $-2M.

Over the past 5 quarters, CytoMed Therapeutics Ltd has demonstrated a growth trajectory, with revenue expanding from $-154,876 to $268,662. Investors analyzing GDTC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GDTC Dividend Yield and Income Analysis

CytoMed Therapeutics Ltd (GDTC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GDTC Momentum and Technical Analysis Profile

CytoMed Therapeutics Ltd (GDTC) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 64/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

GDTC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CytoMed Therapeutics Ltd (GDTC) ranks #591 out of 838 stocks based on the Blank Capital composite score. This places GDTC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GDTC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GDTC vs S&P 500 (SPY) comparison to assess how CytoMed Therapeutics Ltd stacks up against the broader market across all factor dimensions.

GDTC Next Earnings Date

No upcoming earnings date has been announced for CytoMed Therapeutics Ltd (GDTC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GDTC? — Investment Thesis Summary

The quantitative profile for CytoMed Therapeutics Ltd suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, CytoMed Therapeutics Ltd (GDTC) earns a Reduce rating with a composite score of 29.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GDTC stock.

Related Resources for GDTC Investors

Explore more research and tools: GDTC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GDTC head-to-head with peers: GDTC vs AZN, GDTC vs SLGL, GDTC vs VMD.